Loading...
Silence Therapeutics plc
SLNCF•PNK
Healthcare
Biotechnology
$1.60
$0.00(0.00%)
Silence Therapeutics plc (SLNCF) Financial Performance & Income Statement Overview
Review Silence Therapeutics plc’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
70.47%
↑ 70.47%
Operating Income Growth
-27.65%
↓ 27.65%
Net Income Growth
-4.72%
↓ 4.72%
Operating Cash Flow Growth
-71.89%
↓ 71.89%
Operating Margin
-272.02%
↓ 272.02%
Gross Margin
69.88%
↑ 69.88%
Net Profit Margin
-214.05%
↓ 214.05%
ROE
-87.49%
↓ 87.49%
ROIC
-43.57%
↓ 43.57%
Silence Therapeutics plc (SLNCF) Income Statement & Financial Overview
Review Silence Therapeutics plc's (SLNCF) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $142000.00 | $24.33M | $1.14M | $598000.00 |
| Cost of Revenue | $54000.00 | $1.61M | $2.77M | $2.64M |
| Gross Profit | $88000.00 | $22.72M | -$1.63M | -$2.04M |
| Gross Profit Ratio | $0.62 | $0.93 | -$1.43 | -$3.41 |
| R&D Expenses | $20.81M | $20.40M | $15.30M | $10.99M |
| SG&A Expenses | $7.68M | $5.40M | $5.60M | $5.29M |
| Operating Expenses | $28.50M | $25.80M | $20.91M | $16.28M |
| Total Costs & Expenses | $28.55M | $27.41M | $23.68M | $18.92M |
| Interest Income | $0.00 | $886950.00 | $981000.00 | $1.06M |
| Interest Expense | $0.00 | -$11.54M | $8.60M | $183000.00 |
| Depreciation & Amortization | $138000.00 | $119275.00 | $115000.00 | $119000.00 |
| EBITDA | -$28.41M | $7.19M | -$21.44M | -$17.14M |
| EBITDA Ratio | -$200.06 | $0.30 | -$18.77 | -$28.66 |
| Operating Income | -$28.41M | -$3.08M | -$22.54M | -$18.32M |
| Operating Income Ratio | -$200.06 | -$0.13 | -$19.73 | -$30.64 |
| Other Income/Expenses (Net) | -$121000.00 | $26.81M | -$7.62M | $882000.00 |
| Income Before Tax | -$28.53M | $23.74M | -$30.16M | -$17.44M |
| Income Before Tax Ratio | -$200.92 | $0.98 | -$26.41 | -$29.17 |
| Income Tax Expense | $0.00 | $9.56M | -$3.15M | -$1.88M |
| Net Income | -$28.53M | $14.17M | -$27.01M | -$15.56M |
| Net Income Ratio | -$200.92 | $0.58 | -$23.65 | -$26.02 |
| EPS | -$0.60 | $0.31 | -$0.57 | -$0.33 |
| Diluted EPS | -$0.60 | $0.31 | -$0.57 | -$0.33 |
| Weighted Avg Shares Outstanding | $47.23M | $47.22M | $46.74M | $46.74M |
| Weighted Avg Shares Outstanding (Diluted) | $47.23M | $47.22M | $46.74M | $46.74M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan